株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の喘息市場

Global Asthma Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 311855
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
世界の喘息市場 Global Asthma Market 2014-2018
出版日: 2014年09月03日 ページ情報: 英文 91 Pages
概要

米国アレルギー・喘息・免疫学会議(AAAAI)はぜんそくを4つに分類しています:運動誘発性ぜんそく、アレルギー性ぜんそく、職業性ぜんそく、および小児ぜんそく。米国喘息・アレルギー協会(AAFA)はぜんそくを2つに分類しています:アレルギー性喘息および非アレルギー性ぜんそく。ぜんそくは不治の疾患ですが、適切な時の診断とそれに続く定期的な治療により、コントロールが可能です。世界の喘息市場は2013年〜2018年のCAGRで、4.50%の成長が見込まれています。

当レポートでは、世界の喘息市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 市場区分:薬剤クラス別

  • 気管支拡張剤
  • ロイコトリエン拮抗薬
  • 肥満細胞安定剤
  • 免疫抑制剤
  • LABA/ICS配合剤

第8章 世界の気管支拡張剤市場

  • 市場概要
  • 市場規模と予測

第9章 世界のロイコトリエン拮抗薬市場

第10章 世界の肥満細胞安定剤市場

第11章 世界の免疫抑制剤市場

第12章 世界のICS/LABA配合剤市場

第13章 世界のその他の喘息薬市場

第14章 地域区分

  • 世界の喘息市場:地域区分
  • 米国市場
  • ロシア市場
  • インド市場

第15章 発生率・有病率

第16章 購買基準

第17章 市場成長促進要因

第18章 促進要因とその影響

第19章 市場課題

第20章 促進要因と課題の影響

第21章 市場動向

第22章 動向とその影響

第23章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第24章 パイプラインのポートフォリオ

第25章 主要ベンダー分析(事業概要、事業区分、事業戦略、SWOT分析など)

  • AstraZeneca plc
  • Hoffmann La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

第26章 関連レポート

図表リスト

目次
Product Code: IRTNTR4048

About Asthma and its Categories

Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

TechNavio's analysts forecast the Global Asthma Market to grow at a CAGR of 4.50 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma:

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants

TechNavio's report, the Global Asthma Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Asthma Market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

Other Prominent Vendors

  • Abbott
  • Actavis
  • Amgen
  • AptarGroup
  • Astellas
  • Aurobindo
  • Biotest
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cipla
  • Cytos
  • Dainippon Sumitomo
  • Dr. Reddy's Laboratories
  • Glenmark
  • Medicinova
  • Mylan
  • Ono Pharmaceutical
  • Orchid Chemicals and Pharmaceuticals
  • Perrigo
  • Pfizer
  • Ranbaxy
  • Rottapharm Madaus
  • Skyepharma
  • Sosei
  • Sunovion
  • Teva
  • Theravance
  • Vectura

Market Driver

  • Rise in Prevalence of Disease

For a full, detailed list, view our report

Market Challenge

  • Unknown Etiology of Disease

For a full, detailed list, view our report

Market Trend

  • Popularity of Combination Therapies

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Class of Drugs

  • 07.1. Bronchodilators
  • 07.2. Leukotriene Antagonists
  • 07.3. Mast Cell Stabilizers
  • 07.4. Immunosuppressants
  • 07.5. Combination of LABA/ICS

08. Global Bronchodilators Market

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast

09. Global Leukotriene Antagonists Market

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast

10. Global Mast Cell Stabilizers Market

  • 10.1. Market Overview
  • 10.2. Market Size and Forecast

11. Global Immunosuppressants Market

  • 11.1. Market Overview
  • 11.2. Market Size and Forecast

12. Global Combination of ICS/LABA Market

  • 12.1. Market Overview
  • 12.2. Market Size and Forecast

13. Global Other Asthma Drugs Market

  • 13.1. Market Overview
  • 13.2. Market Size and Forecast

14. Geographical Segmentation

  • 14.1. Global Asthma Market by Geographical Segmentation 2013-2018
  • 14.2. Asthma Market in the US
    • 14.2.1. Market Overview
    • 14.2.2. Market Size and Forecast
  • 14.3. Asthma Market in the Russia
    • 14.3.1. Market Overview
    • 14.3.2. Market Size and Forecast
  • 14.4. Asthma Market in the India
    • 14.4.1. Market Overview
    • 14.4.2. Market Size and Forecast

15. Rate of Incidence and Prevalence

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

  • 23.1. Competitive Scenario
    • 23.1.1. Key News
    • 23.1.2. Mergers and Acquisitions
  • 23.2. Market Share Analysis 2013
    • 23.2.1. AstraZeneca
    • 23.2.2. GlaxoSmithKline
    • 23.2.3. Merck
    • 23.2.4. Novartis
    • 23.2.5. Roche
  • 23.3. Other and Future Prominent Vendors

24. Pipeline Portfolio

25. Key Vendor Analysis

  • 25.1. AstraZeneca plc
    • 25.1.1. Key Facts
    • 25.1.2. Business Description
    • 25.1.3. Business Segmentation
    • 25.1.4. Business Strategy
    • 25.1.5. Revenue by Business Segmentation
    • 25.1.6. Revenue Comparison 2011-2013
    • 25.1.7. Sales Revenue by Geographical Segmentation
    • 25.1.8. Key Developments
    • 25.1.9. SWOT Analysis
  • 25.2. Hoffmann La Roche
    • 25.2.1. Key Facts
    • 25.2.2. Business Overview
    • 25.2.3. Business Segmentation by Revenue 2013
    • 25.2.4. Business Segmentation by Revenue 2012 and 2013
    • 25.2.5. Geographical Segmentation by Revenue 2013
    • 25.2.6. Business Strategy
    • 25.2.7. Recent Developments
    • 25.2.8. SWOT Analysis
  • 25.3. GlaxoSmithKline
    • 25.3.1. Key Facts
    • 25.3.2. Business Overview
    • 25.3.3. Business Segmentation
    • 25.3.4. Business Segmentation by Revenue 2012 and 2013
    • 25.3.5. Sales by Geography
    • 25.3.6. Pipeline Products
    • 25.3.7. Business Strategy
    • 25.3.8. Key Information
    • 25.3.9. SWOT Analysis
  • 25.4. Merck
    • 25.4.1. Key Facts
    • 25.4.2. Business Overview
    • 25.4.3. Business Segmentation by Revenue 2013
    • 25.4.4. Business Segmentation by Revenue 2012 and 2013
    • 25.4.5. Sales by Geography
    • 25.4.6. Business Strategy
    • 25.4.7. Key Developments
    • 25.4.8. SWOT Analysis
  • 25.5. Novartis
    • 25.5.1. Key Facts
    • 25.5.2. Business Overview
    • 25.5.3. Business Segmentation by Revenue 2013
    • 25.5.4. Business Segmentation by Revenue 2012 and 2013
    • 25.5.5. Sales by Geography
    • 25.5.6. Business Strategy
    • 25.5.7. Key Developments
    • 25.5.8. SWOT Analysis

26. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Asthma Market 2014-2018 (US$ million)
  • Exhibit 3: Global Asthma Market Segmentation by Class of Drugs
  • Exhibit 4: Global Asthma Market Segmentation by Class of Drugs 2013
  • Exhibit 5: Global Bronchodilators Market 2013-2018 (US$ million)
  • Exhibit 6: Global Leukotriene Antagonists Market 2013-2018 (US$ million)
  • Exhibit 7: Global Mast Cell Stabilizers Market 2013-2018 (US$ million)
  • Exhibit 8: Global Immunosuppressants Market 2013-2018 (US$ million)
  • Exhibit 9: Global Combination of ICS/LABA Market 2013-2018 (US$ million)
  • Exhibit 10: Global Other Asthma Drugs Market 2013-2018 (US$ million)
  • Exhibit 11: Global Asthma Market by Geographical Segmentation 2013
  • Exhibit 12: Asthma Market in the US 2013-2018 (US$ million)
  • Exhibit 13: Asthma Market in Russia 2013-2018(US$ million)
  • Exhibit 14: Asthma Market in India 2013-2018 (US$ million)
  • Exhibit 15: Prescription Trend Chart of the Popular Asthma Drugs in the US 2013
  • Exhibit 16: Global Asthma Market Share Analysis 2013
  • Exhibit 17: Global Sales of Symbicort 2009-2012 (in US$ million)
  • Exhibit 18: Geography-wise Sales of Symbicort 2009-2012 (US$ million)
  • Exhibit 19: Global Sales of Pulmicort 2009-2012 (US$ million)
  • Exhibit 20: Geography-wise Sales of Pulmicort 2009-2012 (US$ million)
  • Exhibit 21: Global Sales of Singulair 2011-2013 (US$ million)
  • Exhibit 22: Global Sales of Dulera 2011-2013 (US$ million)
  • Exhibit 23: Global Sales Forecast of Dulera 2013-2016 (US$ million)
  • Exhibit 24: Pipeline Snapshot of Asthma Drugs
  • Exhibit 25: Sales Forecast of QMF-149 2016-2018 (US$ million)
  • Exhibit 26: AstraZeneca plc: Business Segmentation
  • Exhibit 27: AstraZeneca plc: Revenue by Business Segmentation2013
  • Exhibit 28: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 29: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 30: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 31: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 32: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
  • Exhibit 33: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
  • Exhibit 34: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 35: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 36: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 37: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 38: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 39: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 40: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 41: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 42: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 43: Novartis AG: Sales by Geography 2013
Back to Top